Search

Your search keyword '"HIV Protease Inhibitors administration & dosage"' showing total 7 results
Start Over Descriptor "HIV Protease Inhibitors administration & dosage" Language russian
7 results on '"HIV Protease Inhibitors administration & dosage"'

1. [Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].

Author

Moshkovich GF and Minaeva SV

Subjects
Adult, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Atazanavir Sulfate, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes immunology, Darunavir, Drug Administration Schedule, Drug Therapy, Combination, Female, HIV Infections immunology, HIV Infections virology, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, HIV Protease Inhibitors therapeutic use, Humans, Male, Oligopeptides administration & dosage, Oligopeptides adverse effects, Pyridines administration & dosage, Pyridines adverse effects, RNA, Viral metabolism, Ritonavir administration & dosage, Ritonavir adverse effects, Ritonavir therapeutic use, Sulfonamides administration & dosage, Sulfonamides adverse effects, Time Factors, Viral Load, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Oligopeptides therapeutic use, Pyridines therapeutic use, Sulfonamides therapeutic use
Abstract

Aim: To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load., Materials and Methods: The investigators evaluated the clinical, immunological, and virological efficiency of treatment: the time course of changes in CD4+ lymphocyte levels and viral load at the beginning and at 12, 24, 48, 72, and 96 weeks of antiviral therapy, as well as adverse reactions., Results: The virological effect of once daily darunavir/ritonavir 800/100 mg was highly competitive with that of atazanavir/ritonavir: at 96 weeks of treatment, HIV RNA <120 copies/ml was achieved in 95% of the patients in both treatment groups. A combination of once daily darunavir/ritonavir 800/100 mg ensured a more marked immunological improvement: a difference in the increment (77.1 in 1 μl) of CD4+ lymphocyte count in patients who took darunavir (362.2 in μl) and in those who used atazanavir (285.1 in μl). In the patients who received darunavir, diarrhea, nausea, and headache were observed at the same frequency as in those who had atazanavir., Conclusion: The use of the test agents used in the ARVT has shown their efficacy and good tolerability.

Published
2014

2. [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].

Author

Galegov GA

Subjects
Acquired Immunodeficiency Syndrome drug therapy, Drug Combinations, Drug Resistance, Viral, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors therapeutic use, Humans, Lopinavir, Pyrimidinones administration & dosage, Ritonavir administration & dosage, HIV Infections drug therapy, Pyrimidinones therapeutic use, Ritonavir therapeutic use
Published
2007

3. [Decrease of HIV-1 replicative capacity after serial passage in MT-4 cells under conditions of the combined antiretroviral therapy].

Author

Selimova LM, Khanina TA, and Galegov GA

Subjects
Anti-HIV Agents administration & dosage, Cell Line, Drug Synergism, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors pharmacology, HIV-1 physiology, Humans, Interferon-alpha administration & dosage, Interferon-alpha pharmacology, Reverse Transcriptase Inhibitors administration & dosage, T-Lymphocytes drug effects, T-Lymphocytes virology, Virus Replication drug effects, Anti-HIV Agents pharmacology, HIV-1 drug effects, Reverse Transcriptase Inhibitors pharmacology
Abstract

The replicative activity of HIV-1/IIIB was determined in MT-4 cells under conditions of combined HIV reverse transcriptase and protease inhibitors in the presence of four different drug cocktails: (1) phosphazide, didanosine, nevirapine; (2) stavudine, didanosine, nevirapine; (3) phosphazide, didanosine, nevirapine, indinavir; (4) stavudine, didanosine, nevirapine, indinavir. The concentration of every inhibitor was 10 times higher than the 50% effective concentration. Alpha interferon was used as a natural antiretroviral agent in addition. The virus was subjected to 5 serial passages in the presence of the drug cocktails and then to 5 serial passages without the agents using cocultivation of infected and uninfected cells at ratio 1:5 to increase virus activity. Virus replication in the presence of all the drug combinations resulted in the appearance of HIV-1 variants with low replicative activity that was insignificantly increased during further passages even without the antiretroviral agents. If extrapolated to the clinical practice, these results indicate that all the drug cocktails were effective inhibitors of HIV-1 replication because the virus variants with high replicative activity did not emerge. Moreover, the results showed that the clinical use of the drug cocktails was promising.

Published
2003

4. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].

Author

Ershov FI, Kas'ianova NV, and Vasil'ev AN

Subjects
HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, Humans, Lopinavir, Pyrimidinones administration & dosage, Pyrimidinones adverse effects, Ritonavir adverse effects, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, Pyrimidinones therapeutic use, Ritonavir therapeutic use
Published
2002

5. [A novel anti-HIV agent--agenerase].

Author

Ershov FI, Kas'ianova NV, and Vasil'ev AN

Subjects
Carbamates, Drug Therapy, Combination, Furans, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, Humans, Sulfonamides administration & dosage, Sulfonamides adverse effects, HIV Protease Inhibitors therapeutic use, Sulfonamides therapeutic use
Published
2002

6. [Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].

Author

Selimova LM, Kraevskiĭ AA, and Galegov GA

Subjects
Anti-HIV Agents administration & dosage, Azides administration & dosage, Cell Line, Drug Resistance, Microbial, HIV Protease Inhibitors administration & dosage, HIV-1 physiology, Humans, Indinavir administration & dosage, Microbial Sensitivity Tests, Reverse Transcriptase Inhibitors administration & dosage, Thymidine administration & dosage, Thymidine pharmacology, Virus Replication drug effects, Anti-HIV Agents pharmacology, Azides pharmacology, HIV Protease Inhibitors pharmacology, HIV-1 drug effects, Indinavir pharmacology, Organophosphonates, Reverse Transcriptase Inhibitors pharmacology, Thymidine analogs & derivatives, Zidovudine pharmacology
Published
1999

7. [Synthetic HIV proteinase inhibitors and new prospects for drug therapy of HIV infections and AIDS].

Author

Galegov GA

Subjects
Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacokinetics, CD4 Lymphocyte Count, Drug Resistance, Microbial genetics, Drug Therapy, Combination, HIV genetics, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors pharmacokinetics, Humans, Polymerase Chain Reaction, Viral Load, Acquired Immunodeficiency Syndrome drug therapy, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use
Published
1997

Catalog

Books, media, physical & digital resources
See catalog results